RXRX Earnings Recursion Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–27 of 27
| Q2 2026 | 2026-06-30 | -0.47 | 2026-08-05 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.22 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -1.44 | 2026-02-25 | 10-K |
| Q3 2025 | 2025-09-30 | -1.27 | 2025-11-05 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.91 | 2026-08-05 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.50 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -1.69 | 2026-02-25 | 10-K |
| Q3 2025 | 2024-09-30 | -1.12 | 2025-11-05 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.79 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.39 | 2025-05-05 | 10-Q |
| FY 2025 | 2023-12-31 | -1.58 | 2026-02-25 | 10-K |
| Q3 2024 | 2023-09-30 | -1.16 | 2024-11-06 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.71 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.34 | 2024-05-09 | 10-Q |
| FY 2024 | 2022-12-31 | -1.36 | 2025-02-28 | 10-K |
| Q3 2023 | 2022-09-30 | -1.06 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.71 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.33 | 2023-05-08 | 10-Q |
| FY 2023 | 2021-12-31 | -1.49 | 2024-02-29 | 10-K |
| Q3 2022 | 2021-09-30 | -1.10 | 2022-11-08 | 10-Q |
| Q2 2021 | 2021-06-30 | -0.91 | 2021-08-13 | 10-Q |
| Q1 2022 | 2021-03-31 | -1.33 | 2022-05-10 | 10-Q |
| FY 2022 | 2020-12-31 | -3.99 | 2023-02-27 | 10-K |
| Q3 2021 | 2020-09-30 | -2.82 | 2021-11-10 | 10-Q |
| Q2 2021 | 2020-06-30 | -1.73 | 2021-08-13 | 10-Q |
| Q1 2021 | 2020-03-31 | -0.85 | 2021-05-12 | 10-Q |
| FY 2021 | 2019-12-31 | -2.87 | 2022-03-23 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.